Back to search

University of Leeds

Chemical approaches towards elucidating glioblastoma biology

Abstract

dc:description.abstract

Glioblastoma multiforme (GBM) is the most aggressive, infiltrative brain cancer. Tumour recurrence is common and accounts for the poor 5-year survival rates of GBM (<10%). The ability to re-grow the tumour after surgical removal of the tumour bulk has been attributed to cells with stem cell-like phenotypes, termed glioma stem cells (GSCs). Identification of molecular GSC vulnerabilities targetable by therapeutic agents is urgently required. In this context, I examined the potential anti-GSC effect of KHS101, an experimental compound that induces differentiation in neural progenitor cells in vitro and in vivo. Interestingly, in patient-derived GSCs, KHS101 selectively reduced viability. KHS101 cytotoxicity was associated with a vacuolisation/autophagy phenotype, and loss of clonogenicity of GSCs. Consistently, KHS101 significantly reduced xenograft tumour growth and invasion and prolonged survival of mice bearing GSC-derived tumours. Analysis of the mechanism of action of KHS101 indicated the disruption of oxidative phosphorylation leading to metabolic exhaustion of GSCs. To go beyond the possibilities of single agent treatment, I explored the potential of a combination therapy integrating oncolytic virotherapy with coxsackievirus A21 (CVA21). Targeting of tumour cells by CVA21 requires surface expression of Intercellular Adhesion Molecule-1 (ICAM-1), which is a limiting factor in GBM tumours. Notably, genetic manipulation of GSCs showed that expression of ICAM-1 is sufficient to increase susceptibility to CVA21. To identify ICAM-1 inducing compounds, I carried out a focused combination compound screen for the induction of ICAM1 expression in GSCs. From a panel of 23 compounds, I identified combined retinoic acid (RA) and KHS101 as an efficient ICAM1 mRNA up-regulation treatment. RA/KHS101 also significantly increased surface expression of ICAM-1 protein on GSCs. Notably, RA/KHS101-induced ICAM-1 expression rendered GSCs vulnerable to CVA21-mediated oncolysis in vitro. Hence, a combination of pharmacological treatment and oncolytic virotherapy could complement available chemo-/radiotherapy by eliminating the GSC population and thus preventing tumour recurrence.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Leeds
Year dc:date.issued
2016

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Kuchler, Verena Bettina
Advisors dc:contributor.advisor
  • Wurdak, Heiko
  • Errington-Mais, Fiona

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Identifier
uk.bl.ethos.698257

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Kuchler, Verena Bettina. Chemical approaches towards elucidating glioblastoma biology. doctoral thesis, University of Leeds, 2016.